Global 3D Bioprinting Market By Technology (Magnetic levitation Bioprinting, Laser-assisted Bioprinting) By Materials (Living Cells, Extracellular Matrices, and Hydrogels), By Applications (Medical, Dental, Bioinks, and Biosensors), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The global 3D bioprinting market size is expected to be worth around USD 84.9 billion by 2032 from USD 19.8 billion in 2022, growing at a CAGR of 16.1% during the forecast period from 2022 to 2032.

The growth of the 3D bioprinting market is due to the less number of organ donors and the aging population suffering from chronic respiratory diseases. Increasing investment in R&D, advancement in technology, and increasing incidence of chronic diseases are other serious impact attributes that are likely to drive market growth during the forecast period.

3D bioprinting is a form of additive manufacturing that uses 3D printing to produce biomedical parts that mimic as closely as possible the characteristics of natural tissues. Generally, 3D bioprinting uses a layer-by-layer method for the deposition of materials called bio inks in order to create tissue-like structures that are then used in the tissue engineering and medical fields.

3D bioprinting is commonly used to develop tissue and organ structures that can be used for drug research and development, scaffolds, and the development of medical implants. Additionally, 3D bioprinting has begun incorporating scaffold printing that can be used to reconstruct joints and ligaments. 3D bioprinting technology contributes to tremendous advances in the field of medical tissue engineering by enabling the study of innovative materials known as biomaterials.

Market Scope

Technology Analysis

In terms of technology inkjet-based bioprinting segment dominated the market in 2022

Based on technology, the 3D bioprinting market is segmented into magnetic levitation bioprinting, laser-assisted bioprinting, and inkjet-based bioprinting. Inkjet-based bioprinting segment accounts for the largest share of revenue of 39.0% in 2022, as it enables complex living tissues or organs to be printed on culture substrates using biomaterials as bio-ink. The widespread adoption of inkjet technology in the medical sector is contributing to the growth of this segment.

This work presents research trends in inkjet printing as a bio-applicable technology, especially in the fields of tissue engineering and drug delivery systems. This segment is expected to witness significant growth during the forecast period, driven by growing demand and increased reliability.

The magnetic levitation 3D Bioprinting segment is expected to grow at the fastest CAGR of 15.1% in the upcoming years. The thriving growth can be accredited to technology-related profits. Magnetic levitation technology is anticipated to resolve more than 82.0% of 3D bioprinting errors with advanced features, improved speed, and accuracy. These bioprinters are also used for vascular muscle printing, toxicity screening, and human cell regeneration.

Materials Analysis

The living cell segment accounted for the largest market share over the past years

Based on this segment, the 3D bioprinting market is divided into living cells, extracellular matrices, and hydrogels. Among these segments, the living cells segment accounted for the largest market in recent years. The key drivers of revenue growth in this segment are expanding R & D efforts in the regenerative medicine sector, increasing private and public financing in stem cell research, and adopting 3D bioprinting technology.

Furthermore, the hydrogel segment is predicted to dominate the 3D bioprinting market during the forecast period. In tissue engineering applications, the hydrogel is pre-owned for three purposes. They can be used as gap fillers, as transport vectors for bioactive molecules, and as 3D structures that act as scaffolding for cells and help form ideal tissues.

The extracellular matrix is a complex network consisting of an array of multidomain macromolecules organized in a cell/tissue-specific manner. The structures and properties of the extracellular matrices vary from cell to cell.

Application Analysis

In 2022, the medical segment leads the 3D bioprinting market

Based on application, the 3D bioprinting market is segmented into medical, dental, bioinks, and biosensors. The medical segment leads the market by application in 2022 at a rate of 36.8% and is expected to grow at a CAGR of 16.0% during the forecast period. The widespread use of medical drugs to cure various chronic diseases is driving the growth of the 3D bioprinting market.

In addition, the growing demand for cost-effective biomedical drugs and applications using this technology is continuing to drive this segment. With the increasing number of participants in the pharmaceutical industry, the demand for medical drugs is increasing. Millions of people around the world regularly use capsules and pills. As a result, this segment is expected to grow lucratively during the forecast period.

3D bioprinting technology is most widely used for drug reproduction to meet the need to regenerate organs and tissues suitable for transplantation. In the bioprinting process, a biomaterial solution or a mixture of various biomaterials in the hydrogel form, usually encapsulating the desired cell type, known as a bioink, is used to create tissue structure.

Cell-based biosensors have long been reported in biosensor technology. This type of sensor uses live cells as the sensing substrate to detect functional bioanalytics. Several cell types have been used as sensing components in biosensors.

Key Market Segments

By Technology

• Magnetic levitation Bioprinting
• Laser-assisted Bioprinting
• Inkjet-Based Bioprinting

By Materials

• Living Cells
• Extracellular Matrices
• Hydrogels

By Applications

• Medical
• Dental
• Bioinks
• Biosensors

Market Dynamics

Drivers

The emergence of new pathogens propels the market towards the rapid modification of the drug discovery process.

The emergence of new pathogens has caused unexpected epidemics in humans. The COVID-19 pandemic has demonstrated the urgent need for a platform to enable rapid and flexible development of treatments and vaccines to eliminate new pathogens such as SARS-CoV-2. Because the traditional drug development process usually takes 10-15 years to develop safe and effective drugs.

Therefore, modifying the drug discovery process through emerging sophisticated technologies such as 3D bioprinting and printing is attracting increasing interest in accelerating drug discovery. Because the current success rate of the drug when it comes to clinical trials is about 10%.

Research conducted by many scientists from the departments of nanoengineeringNano engineering and bioengineering has stated that 3D bioprinting of human tissue serves as a potential model representing human physiology to provide more accurate results.

With innovations in bioprinting technologies, the market is anticipated to witness higher growth.

Recently, CLECELL, a 3D bioprinting company, introduced a model of respiratory epithelium using its proprietary U-FAB 3D printer coupled with various bioprinting technologies. The respiratory epithelium is a type of tissue that lines most air passages. Foreign particles and pathogens act as a barrier.

Moreover, it also helps in the prevention of tissue damage and infection. Hence, with the increase in demand for this respiratory epithelium model, the 3D bioprinting market is expected to witness growth. Due to these innovations, the market is expected to witness higher growth during the forecast period.

Restraints

Strict regulations, high costs, and a lack of skilled professionals are expected to hinder the 3D bioprinting market growth.

As with any medical application, safety comes first, which is why strict regulations apply to 3D bioprinting. In addition, the cost of organs in 3D bioprinting is difficult to estimate. Factors such as high production and development costs and a lack of skilled professionals are restraining the expansion of the 3D bioprinting market.

In addition, the valuable use of 3D bioprinting requires continuous monitoring of the process, and this procedure varies between platforms due to material differences and uncontrolled process variables. Thus, this factor is also predicted to limit the market’s growth momentum.

Opportunity

3D Bioprinting is expected to offer researchers and healthcare professionals new treatment options and scientific research opportunities.

Artificially creating human tissue, skin, and internal organs may seem like a futuristic dream, but amazingly, so much is happening right now. Advances in 3D printing, and more specifically, bioprinting, are providing researchers and healthcare professionals with new options for treatment and scientific research. In fact, bioprinting could be the future of medicine and personalized healthcare.

Biomaterials, including biolinkers and support gels, used for 3D bioprinting are essential for growing specific cell types to create better products. To overcome the above-mentioned challenges, several biotech companies have focused on developing bioprinted human tissues to study various diseases.

COVID-19 impact analysis

COVID-19 impact increased the demand for 3D bioprinting systems

The recent COVID-19 pandemic has spread across the globe, and even health systems have been overworked. So, in response to the increase in coronavirus cases, various 3D bioprinting communities were responding to global crises by providing their respective skills to reduce the burden on supply chains and governments.

As COVID-19 cases have been increasing every day, there has been an insufficiency of documentation for health professionals as well as the public. The biggest problem was the lack of COVID-19 testing kits. As a result, many 3D bioprinting companies were producing 3D printers and related software on a large scale.  As the number of COVID-19 infections increases steadily, the demand for 3D bioprinters is rising, and the global 3D bioprinting market is estimated to grow rapidly.

The coronavirus pandemic has also sped up the development of drug and vaccine trials as scientists harness new technologies to test patient safety after preclinical trials begin. With the increasing cases of COVID-19, the medical world was also facing shortages of respirators and ventilators.

3D bioprinting was helping to produce respirators and ventilators to overcome shortages of these devices. With the increasing spread of COVID-19, there was a rise in demand for the 3D bioprinting process. Hence, biopharmaceutical companies and pharmaceutical companies came forward to provide help to the healthcare industry, physicians, healthcare workers, and scientists. This positively impacted the bioprinting industry.

Trends

The U.S. FDA is looking into 3D bioprinting as an alternative for the evaluation of drug efficacy and safety.

There are a few recent trends in 3D bioprinting. 3D bioprinters are of particular importance for drug testing and clinical trial applications, which are expected to significantly reduce the need for animal testing. The U.S. Food and Drug Administration has begun looking into 3D bioprinting as an integrated alternative to evaluate drug efficacy and safety.

Factors such as the favorable regulatory guidelines in emerging countries such as India, the existence of a large number of stem cell product pipelines, and the applications of regenerative medicine to treat the disease is expected to bring favorable growth moment for the 3D bioprinting market in the upcoming period.

Regional Analysis

North America dominated the 3D bioprinting market with the largest revenue share of 36.4% in 2022.

On the basis of regional analysis, the 3D bioprinting market covers North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Among these regions, North America accounted for its dominance holding the largest revenue share in the bioprinting market. In North America, the market has the largest revenue share of 36.4% in 2022 and is expected to lead throughout the forecast period. The increasing integration of IT in the healthcare industry is estimated to drive market growth during the forecast period.

According to Worldometer’s 2021 report, approximately 23,370,742 active cases of COVID-19 have been reported in the United States alone through January 18, 2021. There are now more than 50 potential vaccines under development. The government is spending more on research and development to develop a vaccine against the disease. For this reason, there is an increasing need for 3D bioprinting as the technology has been recognized for drug testing and organ transplantation.

Asia Pacific is expected to be the fastest-growing market holding the largest market share during the forecast period.

In Asia Pacific, this market accounts for 28.0% of the revenue share of the 3D bioprinting industry in 2022 and is anticipated to maintain its dominance over the forecast period. Japan and China account for the largest share of revenue in the region due to the increasing incidence of COVID-19 and increased government investment in R&D.

As reported by Worldometer 2021, about 90,810 positive cases of COVID-19 have been reported in China as of January 18, 2021. In addition, increased COVID-19 mortality and shortages of Organ donors are expected to continue to promote market 3D bioprinting technology in this area.

Key Regions

• North America
  • The US
  • Canada

• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe

• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe

• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC

• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Mexico
  • Costa Rica
  • Rest of Latin America

• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Market Share and Key Player Analysis

3D bioprinting has a lot of unique approaches, as is the case in many developing fields, 3D bioprinting has shown potential for profits, and a number of companies are increasingly trying to apply for patents for their product to prevent it from being marketed elsewhere. 

Key market players are involved in developing new strategies, which form a competitive landscape among prominent players.

Key companies emphasize research and development to develop innovative technology applications to gain a competitive advantage. Major players enter into partnerships, mergers, and acquisitions to strengthen their portfolio of applications and production capabilities and set themselves apart from the competition.

3D bioprinting has a lot of unique approaches, as is the case in many developing fields, 3D bioprinting has shown potential for profits, and a number of companies are increasingly trying to apply for patents for their product to prevent it from being marketed elsewhere.

Recent Developments

In July 2022, Triastek, Inc. partnered with Eli Lilly and Company, a company, in the major pharmaceutical industry, to use 3D printing technology. This initiative will concentrate on the target release of drugs in the gut. Triastek concentrates on the thorough investigation of process parameters to ensure drug stability during the release of drugs and also during the formulation 3D printing process and formulation creation.

In August 2022, the Indian Institute of Science (IISc) and CELLINK, a global pioneer of 3D bioprinter development, announced their partnership to construct a 3D bioprinting Centre of Excellence in Bengaluru, India. The center will be located in the Centre for Biosystems Science and Engineering at IISc and provide access to 3D bioprinting systems offering researchers the to make advancements in their projects through specific applications with the objective of improving medical outcomes.

Listed below are some of the major key players in the 3D bioprinting market

Key Market Players

• EnvisionTEC, Inc.
• Organovo Holdings Inc.
• Regemat 3D S.L.
• Bico group ab
• Collplant Biotechnologies Ltd.
• Regenhu
• Cyfuse Biomedical K.K.
• 3D Bioprinting Solutions
• Cellink Global
• Inventia Life Science PTY LTD
• Poietis
• Vivax Bio, LLC
• Allevi
• Aspect Biosystems Ltd.
• Advanced Solutions Life Sciences, LLC
• Rokit Healthcare, Inc.
• Pandorum Technologies pvt. ltd.
• Foldink Life Science Technologies
• Revotek co., ltd.
• Precise Bio

Report Scope